Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Inventory (2016 - 2025)

Veracyte's Inventory history spans 14 years, with the latest figure at $20.5 million for Q4 2025.

  • On a quarterly basis, Inventory fell 5.54% to $20.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.5 million, a 5.54% decrease, with the full-year FY2025 number at $20.5 million, down 5.54% from a year prior.
  • Inventory hit $20.5 million in Q4 2025 for Veracyte, up from $20.3 million in the prior quarter.
  • Over the last five years, Inventory for VCYT hit a ceiling of $25.0 million in Q2 2025 and a floor of $6.3 million in Q1 2021.
  • Historically, Inventory has averaged $15.8 million across 5 years, with a median of $15.2 million in 2022.
  • Biggest five-year swings in Inventory: skyrocketed 141.04% in 2021 and later fell 20.74% in 2023.
  • Tracing VCYT's Inventory over 5 years: stood at $11.2 million in 2021, then rose by 27.34% to $14.3 million in 2022, then grew by 12.83% to $16.1 million in 2023, then surged by 34.86% to $21.8 million in 2024, then fell by 5.54% to $20.5 million in 2025.
  • Business Quant data shows Inventory for VCYT at $20.5 million in Q4 2025, $20.3 million in Q3 2025, and $25.0 million in Q2 2025.